Short-acting insulin analogues (aspart, glulisine, and lispro) are thought to be better than regular human insulin due to faster absorption and faster onset of action, mimicking better the physiological prandial insulin peak of people without diabetes [14, 15] and leading to lower postprandial glucose levels [16]. This evidence concerns the gene INS and diabetes mellitus.